Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Cash & Equivalents (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Cash & Equivalents for 13 consecutive years, with $198.7 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 98.66% to $198.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $198.7 million through Dec 2025, up 98.66% year-over-year, with the annual reading at $198.7 million for FY2025, 98.66% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $198.7 million at Madrigal Pharmaceuticals, down from $295.7 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $622.5 million in Q1 2024, with the low at $33.5 million in Q2 2021.
  • Average Cash & Equivalents over 5 years is $165.8 million, with a median of $100.0 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents soared 814.14% in 2022, then plummeted 70.5% in 2025.
  • Over 5 years, Cash & Equivalents stood at $36.3 million in 2021, then skyrocketed by 814.14% to $331.5 million in 2022, then crashed by 69.86% to $99.9 million in 2023, then rose by 0.1% to $100.0 million in 2024, then soared by 98.66% to $198.7 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $198.7 million, $295.7 million, and $186.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.